Effect of glucagon-like peptide-1 receptor agonists on major adverse cardiovascular events in adults with type 2 diabetes and established atherosclerotic cardiovascular disease: systematic review and meta-analysis of randomised trials.
Updated analysis confirms diabetes medications called GLP-1 agonists protect the heart and kidneys in patients with diabetes and heart disease.
This SR+MA of randomised trials synthesizes cardiovascular outcome evidence for GLP-1 receptor agonists across the T2DM and established ASCVD patient population, providing updated pooled estimates and subgroup analyses relevant to clinical prescribing decisions. While the cardioprotective class effect is well-established from landmark trials, the analysis adds clinical prescribing value for this high-risk population.
What the study was
- Study design
- Systematic review and meta-analysis of randomised trials
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Cardiovasc Endocrinol Metab
Why it surfaced
SR+MA of RCTs provides highest-grade evidence synthesis; GLP-1 RA MACE benefit clinically significant for cardiometabolic context.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.